Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santen Readies India Expansion Via Centaur Alliance

Executive Summary

Japan’s Santen appears set for a scale up in India via an alliance with Centaur Pharmaceuticals. The partners outline to Scrip the broad contours of the India plan.

You may also be interested in...



Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.

India Premier Pushes For Generic Prescriptions But Hurdles Loom

India’s prime minister has declared that doctors should prescribe medicines using only non-proprietary generic names in an effort to reduce medical bills, but the medical fraternity says the move could jeopardize patient safety, while hurdles mean others see only limited pharma industry impact in the short term.

Five Big Pharma Products That Saw Action In India; There’s More To Come

Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC098829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel